Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2022-11-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate issued by a regulatory authority (Zhejiang Provincial Drug Administration). It includes details about the certificate, product names, registration numbers, validity periods, and expected uses. The document also discusses the potential impact on company performance and includes a risk warning. There are no financial statements, no detailed financial analysis, no earnings data, and no mention of a report being attached or published. The document is an official announcement about a regulatory approval related to product registration, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a management or board change announcement, nor a voting result or capital change. It is a regulatory announcement about a certificate obtained. Given the content and nature, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-11-17 Chinese
关于收到《民事裁定书》暨诉讼事项的进展公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from 美康生物科技股份有限公司 regarding the progress of a civil litigation case involving the company and its subsidiary. It details the receipt of a civil ruling, the background of the lawsuit, the withdrawal and re-filing of the case, and the potential impact on the company's profits. There are no financial statements, audit results, or detailed financial data presented. The document is a legal proceeding update rather than a financial report or management discussion. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is 2427 characters, which is consistent with an announcement rather than a full report.
2022-11-11 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the progress of using part of idle raised funds for cash management. It details the amounts, products, dates, and expected yields of financial products purchased with idle raised funds. It references board meeting approvals and risk control measures. The document is relatively short (2715 characters) and does not contain comprehensive financial statements or detailed financial analysis. It is an update on financing activities related to the use of raised funds, specifically cash management of idle raised capital. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or audit. Therefore, the appropriate classification is CAP with high confidence.
2022-11-04 Chinese
关于终止合作备忘录及终止设立产业基金的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 美康生物科技股份有限公司 regarding the termination of a cooperation memorandum and the termination of the establishment of an industrial fund. It details the background of the cooperation, the reasons for termination, and the impact on the company. The document is short (1239 characters), does not contain financial statements or detailed financial data, and is an announcement of a corporate decision rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update since it is about terminating a cooperation and fund setup, not about new financing or capital changes. It is not a Management or Board change announcement either. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-10-25 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司签署合作协议暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (中天国富证券有限公司) regarding the review and opinion on a related-party transaction involving 美康生物科技股份有限公司. It includes extensive information about the transaction, the parties involved, pricing policies, board and supervisory committee approvals, and independent directors' opinions. The document is regulatory in nature but focuses on the audit and verification of a specific related-party transaction rather than a full annual report or earnings release. It does not contain financial statements or earnings data but provides an audit opinion on the transaction's fairness and compliance with regulations. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit opinion on a specific matter, not a full annual report or other category. The document length (6182 characters) and content support this classification with high confidence. Q3 2022
2022-10-25 Chinese
关于签订合作协议暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company about signing a cooperation agreement involving a related party transaction. It includes specifics about the transaction, related party details, pricing policies, board and supervisory committee approvals, and opinions from independent directors and the sponsoring institution. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a significant related party transaction and cooperation agreement. It does not contain financial statements or quarterly/yearly results but focuses on governance and transaction disclosure. This fits the category of Regulatory Filings (RNS), which is the fallback for announcements that do not fit other specific categories and involve compliance and disclosure of corporate actions.
2022-10-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.